<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41677208</PMID><DateCompleted><Year>2026</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2026</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1753-4666</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><PubDate><Year>2026</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Therapeutic advances in respiratory disease</Title><ISOAbbreviation>Ther Adv Respir Dis</ISOAbbreviation></Journal><ArticleTitle>Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies.</ArticleTitle><Pagination><StartPage>17534666261417149</StartPage><MedlinePgn>17534666261417149</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17534666261417149</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/17534666261417149</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Hydrofluoroolefin-1234ze (HFO-1234ze) is a next-generation propellant with 99.9% lower global warming potential (GWP) than hydrofluoroalkane-134a (HFA-134a).</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We report systemic and lung exposure bioequivalence for budesonide/glycopyrrolate/formoterol fumarate (BGF) components with HFO-1234ze versus HFA-134a.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">These phase I, randomized, double-blind, single-dose, 3-way cross-over trials in healthy adults included three phases (screening; three single-dose treatment periods with 3- to 7-day washouts; follow-up).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants were randomized to four BGF inhalations (160/9/4.8&#x2009;&#xb5;g/actuation) with test (HFO-1234ze) or reference (HFA-134a) treatments in one of three sequences, with HFA-134a administered during two of the three treatment periods. For lung exposure, oral activated charcoal was administered before and after treatment. Bioequivalence was considered established if the 90% confidence interval (CI) for the geometric mean ratio (GMR) was within 80%-125% (or expanded limits, if appropriate) for maximum plasma concentration (Cmax), area under the plasma concentration-curve from time zero to the last quantifiable concentration (AUClast) and AUC from time zero to infinity (AUCinf; US approach only).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bioequivalence criteria were met across BGF components. The 90% CI for the GMR was within 80%-125% (or expanded limits) for HFO-1234ze versus HFA-134a, for systemic (GMR: Cmax, 85.41-99.29; AUClast, 95.74-102.48; AUCinf, 90.72-102.58) and lung (GMR: Cmax, 93.39-104.24, AUClast, 97.02-107.76; AUCinf, 101.45-112.22) exposure. No serious adverse events were reported.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Total systemic and lung exposure to all BGF components met bioequivalence criteria for HFO-1234ze versus HFA-134a, with no new or unexpected safety findings. The near-zero GWP HFO-1234ze propellant is a viable replacement for HFA-134a.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">NCT05569421 (clinicaltrials.gov/study/NCT05569421) and NCT05477108 (clinicaltrials.gov/study/NCT05477108).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bednarczyk</LastName><ForeName>Artur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca Pharma Poland, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aurivillius</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4660-5040</Identifier><AffiliationInfo><Affiliation>Respiratory and Immunology, Global Patient Safety, Biopharmaceuticals R&amp;D, AstraZeneca, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jassal</LastName><ForeName>Mandeep</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Mihir</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raphiou</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petullo</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Biometrics, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Biometrics, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heijer</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&amp;D, AstraZeneca, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sychowicz</LastName><ForeName>Klementyna</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca Pharma Poland, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collison</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Operations, Biopharmaceuticals R&amp;D, AstraZeneca, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&amp;D, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Jitendar</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&amp;D, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Parexel, Glendale, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldwater</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Parexel, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillen</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Creek Lane PK, LLC, Waterford, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Mehul</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Respiratory &amp; Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Academy House, 136 Hills Road, Cambridge CB2 8PA, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT05569421</AccessionNumber><AccessionNumber>NCT05477108</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2026</Year><Month>02</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Respir Dis</MedlineTA><NlmUniqueID>101316317</NlmUniqueID><ISSNLinking>1753-4658</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>V92SO9WP2I</RegistryNumber><NameOfSubstance UI="D006024">Glycopyrrolate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000335">Aerosol Propellants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006845">Hydrocarbons, Fluorinated</NameOfSubstance></Chemical><Chemical><RegistryNumber>R40P36GDK6</RegistryNumber><NameOfSubstance UI="C094049">apaflurane</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>W34SHF8J2K</RegistryNumber><NameOfSubstance UI="D000068759">Formoterol Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000069502">Budesonide, Formoterol Fumarate Drug Combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005466">Fluorocarbons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="Y">Lung</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006024" MajorTopicYN="Y">Glycopyrrolate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000335" MajorTopicYN="Y">Aerosol Propellants</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006845" MajorTopicYN="Y">Hydrocarbons, Fluorinated</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001993" MajorTopicYN="Y">Bronchodilator Agents</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068759" MajorTopicYN="Y">Formoterol Fumarate</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069502" MajorTopicYN="Y">Budesonide, Formoterol Fumarate Drug Combination</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005466" MajorTopicYN="N" AutoHM="Y">Fluorocarbons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COPD</Keyword><Keyword MajorTopicYN="N">bioequivalence</Keyword><Keyword MajorTopicYN="N">global warming potential</Keyword><Keyword MajorTopicYN="N">hydrofluoroolefin-1234ze</Keyword><Keyword MajorTopicYN="N">next-generation propellant</Keyword></KeywordList><CoiStatement>Artur Bednarczyk, Magnus Aurivillius, Mandeep Jassal, Mihir Shah, David Petullo, John Xu, Maria Heijer, Klementyna Sychowicz, Kathryn Collison, Carlos Silva, Jitendar Reddy, and Mehul Patel are employees of AstraZeneca and may hold stock and/or stock options in the company. Ibrahim Raphiou is currently at Research Triangle Park, NC, United States. Ronald Goldwater is an employee of Parexel, which was funded by AstraZeneca to conduct this study. Michael Gillen is a contract employee of AstraZeneca and holds stock in the company. David Han is an employee of Parexel, which was funded by AstraZeneca to conduct this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>2</Month><Day>12</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2026</Year><Month>2</Month><Day>12</Day><Hour>12</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2026</Year><Month>2</Month><Day>12</Day><Hour>8</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>2</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41677208</ArticleId><ArticleId IdType="pmc">PMC12901903</ArticleId><ArticleId IdType="doi">10.1177/17534666261417149</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Global Initiative for Asthma. Global strategy for asthma management and prevention, https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf (2024, accessed 26 November 2024).</Citation></Reference><Reference><Citation>Laube BL, Janssens HM, de Jongh FHC, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">21310878</ArticleId></ArticleIdList></Reference><Reference><Citation>Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler technology: formulation development. AAPS PharmSciTech 2014; 15: 434&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3969484</ArticleId><ArticleId IdType="pubmed">24452499</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal B, Gogtay J. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence. Expert Rev Respir Med 2014; 8: 349&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">24802511</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodcock A, Beeh KM, Sagara H, et al. The environmental impact of inhaled therapy: making informed treatment choices. Eur Respir J 2022; 60: 2102106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9301054</ArticleId><ArticleId IdType="pubmed">34916263</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeswani HK, Azapagic A. Life cycle environmental impacts of inhalers. J Clean Prod 2019; 237: 117733.</Citation></Reference><Reference><Citation>
United Nations Environment Programme. The Kigali Amendment (2016): the amendment to the Montreal Protocol agreed by the Twenty-Eighth Meeting of the Parties, https://ozone.unep.org/treaties/montreal-protocol/amendments/kigali-amendment-2016-amendment-montreal-protocol-agreed (2016, accessed 2025 Mar 5).</Citation></Reference><Reference><Citation>
United Nations Environment Programme. The Montreal protocol on substances that deplete the ozone layer, https://ozone.unep.org/treaties/montreal-protocol (2020, accessed 5 June 2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">1506990</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Medicines Agency. Trixeo Aerosphere. Summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/trixeo-aerosphere-epar-product-information_en.pdf (2020, accessed 23 Sep 2025).</Citation></Reference><Reference><Citation>
US Food and Drug Administration. Breztri Aerosphere&#x2122; highlights of prescribing information, https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/9d44f9af-438a-448b-bb5c-dae506e17e49/9d44f9af-438a-448b-bb5c-dae506e17e49_viewable_rendition__v.pdf (2022, accessed 9 July 2025).</Citation></Reference><Reference><Citation>Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med 2020; 383: 35&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">32579807</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med 2018; 6: 747&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pubmed">30232048</ArticleId></ArticleIdList></Reference><Reference><Citation>
Global Initiative for Chronic Obstructive Lung Disease. 2025. 
GOLD Report: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, https://goldcopd.org/2025-gold-report/ (2025, accessed 23 Sep 2025).</Citation></Reference><Reference><Citation>Rabe KF, Martinez FJ, Singh D, et al. Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial. Ther Adv Respir Dis 2021; 15: 17534666211034329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8392797</ArticleId><ArticleId IdType="pubmed">34428980</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study. Am J Respir Crit Care Med 2021; 203: 553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7924571</ArticleId><ArticleId IdType="pubmed">33252985</ArticleId></ArticleIdList></Reference><Reference><Citation>
Honeywell International I. Honeywell and Recipharm to speed development of inhalers with a near-zero global warming potential propellant, https://www.honeywell.com/us/en/press/2023/08/honeywell-and-recipharm-to-speed-development-of-inhalers-with-a-near-zero-global-warming-potential-propellant (2023, accessed 23 June 2025).</Citation></Reference><Reference><Citation>
Intergovernmental Panel on Climate Change. Working Group I Sixth Assessment Report, https://www.ipcc.ch/report/ar6/wg1/downloads/report/IPCC_AR6_WGI_Chapter_07_Supplementary_Material.pdf (2021, accessed 10 June 2025).</Citation></Reference><Reference><Citation>Pritchard JN. The climate is changing for metered-dose inhalers and action is needed. Drug Des Devel Ther 2020; 14: 3043&#x2013;3055.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7410333</ArticleId><ArticleId IdType="pubmed">32801643</ArticleId></ArticleIdList></Reference><Reference><Citation>Aurivillius M, Bednarczyk A, Kokot M, et al. Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential. Pulm Pharmacol Ther 2023; 83: 102245.</Citation><ArticleIdList><ArticleId IdType="pubmed">37607661</ArticleId></ArticleIdList></Reference><Reference><Citation>Hopewell S, Chan AW, Collins GS, et al. CONSORT 2025 statement: updated guideline for reporting randomized trials. Nat Med 2025; 31: 1776&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">40229553</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell NJ, Ganderton D. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology, London, U.K. On 17 April 1998. Respir Med 1999; 93: 123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">10464864</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrystyn H. Methods to identify drug deposition in the lungs following inhalation. Br J Clin Pharmacol 2001; 51: 289&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2014454</ArticleId><ArticleId IdType="pubmed">11318763</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson L, Edsbacker S. Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer. Eur Respir J 1998; 12: 1340&#x2013;1345.</Citation><ArticleIdList><ArticleId IdType="pubmed">9877488</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xe4;helm&#xe4; S, Sairanen U, Haikarainen J, et al. Equivalent lung dose and systemic exposure of budesonide/formoterol combination via Easyhaler and Turbuhaler. J Aerosol Med Pulm Drug Deliv 2015; 28: 462&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4688463</ArticleId><ArticleId IdType="pubmed">25757188</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh D, Collarini S, Poli G, et al. Effect of AeroChamber Plus&#x2122; on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI. Br J Clin Pharmacol 2011; 72: 932&#x2013;939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3244640</ArticleId><ArticleId IdType="pubmed">21615456</ArticleId></ArticleIdList></Reference><Reference><Citation>Leaker BR, Singh D, Nicholson GC, et al. Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease. Respir Res 2019; 20: 132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6599298</ArticleId><ArticleId IdType="pubmed">31253162</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes A, DePetrillo P, Siddiqui S, et al. Pharmacokinetics of co-suspension delivery technology budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF MDI) and budesonide/formoterol fumarate dihydrate (BFF MDI) fixed-dose combinations compared with an active control: a Phase 1, randomized, single dose, crossover study in healthy adults. Clin Pharmacol Drug Dev 2019; 8: 223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6585691</ArticleId><ArticleId IdType="pubmed">29901860</ArticleId></ArticleIdList></Reference><Reference><Citation>
United States Food and Drug Administration. Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA guidance for industry, https://www.fda.gov/media/87219/download (2021, accessed 5 March 2025).</Citation></Reference><Reference><Citation>
European Medicines Agency. Guideline on the investigation of bioequivalence, https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf (2010, accessed 5 March 2025).</Citation><ArticleIdList><ArticleId IdType="pubmed">20070293</ArticleId></ArticleIdList></Reference><Reference><Citation>Darken P, DePetrillo P, Reisner C, et al. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: a Phase I randomized, single-dose, crossover study in healthy adults. Pulm Pharmacol Ther 2018; 50: 11&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">29544728</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Hu C, Yu H, et al. Pharmacokinetics and tolerability of budesonide/glycopyrronium/formoterol fumarate dihydrate and glycopyrronium/formoterol fumarate dihydrate metered dose inhalers in healthy Chinese adults: a randomized, double-blind, parallel-group study. Clin Ther 2019; 41: 897&#x2013;909 e891.</Citation><ArticleIdList><ArticleId IdType="pubmed">30982547</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorinsky P, DePetrillo P, DeAngelis K, et al. Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler administered with and without a spacer: results of a phase I, randomized, crossover trial in healthy adults. Clin Ther 2020; 42: 634&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">32253054</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorinsky P, DePetrillo P, Siddiqui S, et al. Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent. Pulm Pharmacol Ther 2018; 51: 18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">29763659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tothfalusi L, Endrenyi L. Sample sizes for designing bioequivalence studies for highly variable drugs. J Pharm Pharm Sci 2012; 15: 73&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">22365089</ArticleId></ArticleIdList></Reference><Reference><Citation>Tewari SG, Bell JP, Budgen N, et al. Pressurized metered-dose inhalers using next-generation propellant HFO-1234ze(E) deposit negligible amounts of trifluoracetic acid in the environment. Front Environ Sci 2023; 11.</Citation></Reference><Reference><Citation>Hargreaves C, Budgen N, Whiting A, et al. S60 A new medical propellant HFO-1234ze(E): reducing the environmental impact of inhaled medicines [abstract]. Thorax 2022; 77: A38&#x2013;A39.</Citation></Reference><Reference><Citation>Bafadhel M, Rabe KF, Martinez FJ, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: a post-hoc analysis of data from ETHOS. Int J Chron Obstruct Pulmon Dis 2022; 17: 3061&#x2013;3073.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9738173</ArticleId><ArticleId IdType="pubmed">36510486</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimeno F, van der Weele LT, Ko&#xeb;ter GH, et al. Variability of forced oscillation (Siemens Siregnost FD 5) measurements of total respiratory resistance in patients and healthy subjects. Ann Allergy 1993; 71: 56&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8328715</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhand R, Cavanaugh T, Skolnik N. Considerations for optimal inhaler device selection in chronic obstructive pulmonary disease. Cleve Clin J Med 2018; 85: S19&#x2013;S27.</Citation><ArticleIdList><ArticleId IdType="pubmed">29494329</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler DA. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease. Respir Med 2020; 161: 105857.</Citation><ArticleIdList><ArticleId IdType="pubmed">32056720</ArticleId></ArticleIdList></Reference><Reference><Citation>Raphiou I, et al. Am J Respiratory Critical Care Med 2024; 209: A1216.</Citation></Reference><Reference><Citation>Shah M, et al. Am J Respiratory Critical Care Med 2024; 209: A3824.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41344973</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-114X</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical therapeutics</Title><ISOAbbreviation>Clin Ther</ISOAbbreviation></Journal><ArticleTitle>Exposure to Budesonide, Glycopyrronium, and Formoterol With a Next-Generation Propellant Does Not Exceed Exposure With Hydrofluoroalkane-134a Propellant When Administered Via Pressurized Metered-Dose Inhaler With a Spacer.</ArticleTitle><Pagination><StartPage>73</StartPage><EndPage>80</EndPage><MedlinePgn>73-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2025.10.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0149-2918(25)00378-9</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Hydrofluoroalkane-134a (HFA-134a), the propellant in the marketed budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) formulation, has a global warming potential (GWP) that falls above environmental regulation thresholds and therefore will be phased out. With global efforts to minimize carbon emissions, the hydrofluoroolefin-1234ze (HFO-1234ze) propellant, with a &gt;99% lower GWP than HFA-134a, is in development for pressurized metered-dose inhalers (pMDIs). Spacers support drug delivery in patients with poor pMDI inhalation technique, but it is unknown if BGF exposure with HFO-1234ze exceeds that observed with HFA-134a when using a spacer.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This Phase I study assessed systemic BGF component exposure with HFO-1234ze versus HFA-134a when using a spacer, and for HFO-1234ze with and without a spacer. Participants (N = 42) were randomized to BGF with HFA-134a with a spacer (reference), HFO-1234ze with a spacer (test), and HFO-1234ze without a spacer (descriptive treatment) over 3 treatment periods in 1 of 6 sequences. As spacer devices help to increase exposure, the upper limit of the 90% confidence interval (CI) of geometric mean ratios (GMRs) was of interest, and bioequivalence was not included as a study objective.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Analyses demonstrated the upper 90% CI of the GMRs for maximum observed plasma concentration (Cmax) and area under the plasma concentration curve from time zero to the time of the last quantifiable concentration (AUClast) were &lt;125% for all BGF components for HFO-1234ze versus HFA-134a when using a spacer, indicating exposure with HFO-1234ze did not exceed exposure with HFA-134a. Additionally, Cmax was increased for all BGF components with HFO-1234ze when using versus not using a spacer, with the largest increases observed among participants with the lowest exposure when not using a spacer, likely due to poor inhalation technique. No new safety findings, and no deaths or serious adverse events, occurred during the study.</AbstractText><AbstractText Label="IMPLICATIONS" NlmCategory="CONCLUSIONS">These findings provide evidence that may help to support the future use of HFO-1234ze propellant in BGF pMDIs.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pandya</LastName><ForeName>Hitesh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&amp;D, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Mehul</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&amp;D, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillen</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Creek Lane PK, LLC, Waterford, Virginia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reddy</LastName><ForeName>Jitendar</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&amp;D, AstraZeneca, The Discovery Centre, Biomedical Campus, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bednarczyk</LastName><ForeName>Artur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&amp;D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokot</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&amp;D, AstraZeneca, AstraZeneca Pharma Poland, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Yubo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Biometrics, BioPharmaceuticals R&amp;D, AstraZeneca, Mississauga, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heijer</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&amp;D AstraZeneca, M&#xf6;lndal, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersson</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Operations, BioPharmaceuticals R&amp;D, AstraZeneca, M&#xf6;lndal, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petullo</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Biometrics, BioPharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jassal</LastName><ForeName>Mandeep</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Respiratory and Immunology, Clinical Development, BioPharmaceuticals R&amp;D, Gaithersburg, Maryland. Electronic address: mandeep.jassal@astrazeneca.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Ther</MedlineTA><NlmUniqueID>7706726</NlmUniqueID><ISSNLinking>0149-2918</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>V92SO9WP2I</RegistryNumber><NameOfSubstance UI="D006024">Glycopyrrolate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006845">Hydrocarbons, Fluorinated</NameOfSubstance></Chemical><Chemical><RegistryNumber>51333-22-3</RegistryNumber><NameOfSubstance UI="D019819">Budesonide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000335">Aerosol Propellants</NameOfSubstance></Chemical><Chemical><RegistryNumber>R40P36GDK6</RegistryNumber><NameOfSubstance UI="C094049">apaflurane</NameOfSubstance></Chemical><Chemical><RegistryNumber>W34SHF8J2K</RegistryNumber><NameOfSubstance UI="D000068759">Formoterol Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004983">Ethanolamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005466">Fluorocarbons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036501" MajorTopicYN="Y">Metered Dose Inhalers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006024" MajorTopicYN="Y">Glycopyrrolate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006845" MajorTopicYN="Y">Hydrocarbons, Fluorinated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019819" MajorTopicYN="Y">Budesonide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000335" MajorTopicYN="Y">Aerosol Propellants</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068759" MajorTopicYN="N">Formoterol Fumarate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001993" MajorTopicYN="Y">Bronchodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004983" MajorTopicYN="Y">Ethanolamines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036503" MajorTopicYN="N">Inhalation Spacers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005466" MajorTopicYN="N">Fluorocarbons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AeroChamber Plus Flow-Vu&#xae; spacer device</Keyword><Keyword MajorTopicYN="N">Budesonide/glycopyrronium/formoterol fumarate dihydrate</Keyword><Keyword MajorTopicYN="N">Hydrofluoroolefin-1234ze</Keyword><Keyword MajorTopicYN="N">Next-generation propellant</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">Pressurized metered-dose inhaler</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Hitesh Pandya reports a relationship with AstraZeneca that includes: employment and equity or stocks. Mehul Patel reports a relationship with AstraZeneca that includes: employment and equity or stocks. Michael Gillen reports a relationship with AstraZeneca that includes: contract employment and equity or stocks. Jitendar Reddy reports a relationship with AstraZeneca that includes: employment and equity or stocks. Artur Bednarczyk reports a relationship with AstraZeneca that includes: employment and equity or stocks. Marek Kokot reports a relationship with AstraZeneca that includes employment. Yubo Tan reports a relationship with AstraZeneca that includes: employment and equity or stocks. Maria Heijer reports a relationship with AstraZeneca that includes: employment and equity or stocks. Magdalena Andersson reports a relationship with AstraZeneca that includes: employment and equity or stocks. David Petullo reports a relationship with AstraZeneca that includes employment. Mandeep Jassal reports a relationship with AstraZeneca that includes: employment and equity or stocks. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>12</Month><Day>5</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>12</Month><Day>4</Day><Hour>22</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41344973</ArticleId><ArticleId IdType="doi">10.1016/j.clinthera.2025.10.011</ArticleId><ArticleId IdType="pii">S0149-2918(25)00378-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">41318994</PMID><DateCompleted><Year>2025</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>12</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2052-1707</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Pharmacology research &amp; perspectives</Title><ISOAbbreviation>Pharmacol Res Perspect</ISOAbbreviation></Journal><ArticleTitle>A Single Dose, Randomized, Open-Label, Cross-Over Bioequivalence Study of Budesonide Pressurized Metered-Dose Inhaler in Healthy Chinese Subjects.</ArticleTitle><Pagination><StartPage>e70197</StartPage><MedlinePgn>e70197</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70197</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/prp2.70197</ELocationID><Abstract><AbstractText>Budesonide is a first-line inhaled glucocorticoid (ICS) for asthma treatment in adults and children. The purpose of this study was to compare the pharmacokinetics and assess the bioequivalence between two budesonide pressurized metered-dose inhalers (pMDIs, 200&#x2009;&#x3bc;g/actuation&#x2009;&#xd7;&#x2009;1 actuation) in healthy Chinese subjects. The study was conducted in 32 healthy Chinese subjects using a single-center, randomized, open-label, four-period and crossover design with a 3-day washout between periods. Blood samples were collected up to 16&#x2009;h post-dose. Plasma concentrations of budesonide were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Reference-scaled average bioequivalence (RSABE) or average bioequivalence (ABE) method was applied to evaluate the bioequivalence, on the basis of the within-subject standard deviation (S<sub>WR</sub>) of the reference product (Budiair), and the safety was also assessed. Eventually, 31 subjects completed this study. For the maximum concentration (C<sub>max</sub>) (within-subject standard deviation, S<sub>WR</sub>&#x2009;&#x2265;&#x2009;0.294), the RSABE method showed a geometric mean ratio (GMR) of 97.13% with a 95% upper confidence bound of &lt;&#x2009;0. For the area under plasma concentration-time curve from time zero to the last measurable concentration (AUC<sub>0-t</sub>) and the area under plasma concentration-time curve extrapolated to infinity (AUC<sub>0-&#x221e;</sub>) (S<sub>WR</sub> &lt;&#x2009;0.294), ABE yielded GMRs of 104.81% and 104.61%, with 90% confidence intervals (CIs) of 99.98%-109.86% and 99.81%-109.63%, respectively. All adverse events (AEs) were mild to moderate and transient, with no serious adverse events (SAEs) reported. The two budesonide pMDIs (200&#x2009;&#x3bc;g) were bioequivalent and well tolerated in healthy Chinese subjects. Trial Registration: Chinese Clinical Trial Registry, Registration No. CTR20244600; ClinicalTrials.gov identifier: NCT06924190.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Pharmacology Research &amp; Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Shaohong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lunan Better Pharmaceutical Co. LTD, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Weiguo</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Lunan Better Pharmaceutical Co. LTD, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Lairong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Lunan Better Pharmaceutical Co. LTD, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Zhenzhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Que</LastName><ForeName>Linling</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3380-8105</Identifier><AffiliationInfo><Affiliation>Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Yunfei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Jinxia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lunan Better Pharmaceutical Co. LTD, Shandong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT06924190</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Lunan Better Pharmaceutical Co., LTD</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacol Res Perspect</MedlineTA><NlmUniqueID>101626369</NlmUniqueID><ISSNLinking>2052-1707</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>51333-22-3</RegistryNumber><NameOfSubstance UI="D019819">Budesonide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Population" UI="C000724312">Chinese people</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019819" MajorTopicYN="Y">Budesonide</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="Y">Glucocorticoids</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036501" MajorTopicYN="Y">Metered Dose Inhalers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N" AutoHM="Y">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioequivalence</Keyword><Keyword MajorTopicYN="N">budesonide</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">pressurized metered dose inhaler</Keyword></KeywordList><CoiStatement>Shaohong Yin, Weiguo Huang, Lairong Ding, and Jinxia Gao are employees of Lunan Better Pharmaceutical Co. LTD. Other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>11</Month><Day>30</Day><Hour>1</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>11</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41318994</ArticleId><ArticleId IdType="pmc">PMC12664903</ArticleId><ArticleId IdType="doi">10.1002/prp2.70197</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ora J., De Marco P., Gabriele M., et&#xa0;al., &#x201c;Exercise&#x2010;Induced Asthma: Managing Respiratory Issues in Athletes,&#x201d; Journal of Functional Morphology and Kinesiology 9, no. 1 (2024): 15, 10.3390/jfmk9010015.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jfmk9010015</ArticleId><ArticleId IdType="pmc">PMC10801521</ArticleId><ArticleId IdType="pubmed">38249092</ArticleId></ArticleIdList></Reference><Reference><Citation>Schleich F., Bougard N., Moermans C., Sabbe M., and Louis R., &#x201c;Cytokine&#x2010;Targeted Therapies for Asthma and COPD,&#x201d; European Respiratory Review 32, no. 168 (2023): 220193, 10.1183/16000617.0193-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/16000617.0193-2022</ArticleId><ArticleId IdType="pmc">PMC10113955</ArticleId><ArticleId IdType="pubmed">37076177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain M. and Liu G., &#x201c;Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons,&#x201d; Cells 13, no. 5 (2024): 384, 10.3390/cells13050384.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells13050384</ArticleId><ArticleId IdType="pmc">PMC10931088</ArticleId><ArticleId IdType="pubmed">38474348</ArticleId></ArticleIdList></Reference><Reference><Citation>Mel&#xe9;n E., Zar H. J., Siroux V., et&#xa0;al., &#x201c;Asthma Inception: Epidemiologic Risk Factors and Natural History Across the Life Course,&#x201d; American Journal of Respiratory and Critical Care Medicine 210, no. 6 (2024): 737&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11418887</ArticleId><ArticleId IdType="pubmed">38981012</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding S. and Zhong C., &#x201c;Exercise and Asthma,&#x201d; Advances in Experimental Medicine and Biology 1228 (2020): 369&#x2013;380, 10.1164/rccm.202312-2249SO.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202312-2249SO</ArticleId><ArticleId IdType="pubmed">32342471</ArticleId></ArticleIdList></Reference><Reference><Citation>Srichana T., Juthong S., Thawithong E., Supaiboonpipat S., and Soorapan S., &#x201c;Clinical Equivalence of Budesonide Dry Powder Inhaler and Pressurized Metered Dose Inhaler,&#x201d; Clinical Respiratory Journal 10, no. 1 (2016): 74&#x2013;82, 10.1111/crj.12188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/crj.12188</ArticleId><ArticleId IdType="pubmed">25043636</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Connell E. J., &#x201c;Review of the Unique Properties of Budesonide,&#x201d; Clinical Therapeutics 25, no. Suppl C (2003): C42&#x2013;C60, 10.1016/s0149-2918(03)80305-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0149-2918(03)80305-3</ArticleId><ArticleId IdType="pubmed">14642803</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin W., Zhao Z., and Zhou D., &#x201c;Effect of Montelukast Sodium Combined With Budesonide Aerosol on Airway Function and T Lymphocytes in Asthmatic Children,&#x201d; Pakistan Journal of Medical Sciences 38, no. 5 (2022): 1265&#x2013;1270, 10.12669/pjms.38.5.5749.</Citation><ArticleIdList><ArticleId IdType="doi">10.12669/pjms.38.5.5749</ArticleId><ArticleId IdType="pmc">PMC9247798</ArticleId><ArticleId IdType="pubmed">35799724</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyseng&#x2010;Williamson K. A. and Simpson D., &#x201c;Budesonide/Formoterol Pressurized Metered&#x2010;Dose Inhaler,&#x201d; Drugs 68, no. 13 (2008): 1855&#x2013;1864, 10.2165/00003495-200868130-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003495-200868130-00005</ArticleId><ArticleId IdType="pubmed">18729536</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly R. and Seale J. P., &#x201c;Clinical Pharmacokinetics of Inhaled Budesonide,&#x201d; Clinical Pharmacokinetics 40, no. 6 (2001): 427&#x2013;440, 10.2165/00003088-200140060-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00003088-200140060-00004</ArticleId><ArticleId IdType="pubmed">11475468</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Li Y., Xu B., et&#xa0;al., &#x201c;Pharmacokinetics and Bioequivalence of a Generic and a Branded Budesonide Nasal Spray in Healthy Chinese Subjects,&#x201d; Clinical Pharmacology in Drug Development 11, no. 4 (2022): 516&#x2013;522, 10.1002/cpdd.1036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.1036</ArticleId><ArticleId IdType="pubmed">34783456</ArticleId></ArticleIdList></Reference><Reference><Citation>Maes A., DePetrillo P., Siddiqui S., Reisner C., and Dorinsky P., &#x201c;Pharmacokinetics of Co&#x2010;Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed&#x2010;Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single&#x2010;Dose, Crossover Study in Healthy Adults,&#x201d; Clinical Pharmacology in Drug Development 8, no. 2 (2019): 223&#x2013;233, 10.1002/cpdd.585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpdd.585</ArticleId><ArticleId IdType="pmc">PMC6585691</ArticleId><ArticleId IdType="pubmed">29901860</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Medical Products Administration
, &#x201c;Guidelines for Bioequivalence Studies of Generic Oral Inhaled Products,&#x201d;
https://www.cde.org.cn/zdyz/downloadAtt?idCODE=77dd20dfcf61c41b2eb5b59e14bdd9dc.</Citation></Reference><Reference><Citation>Lu D., Lee S. L., Lionberger R. A., et&#xa0;al., &#x201c;International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences,&#x201d; AAPS Journal 17, no. 3 (2015): 546&#x2013;557, 10.1208/s12248-015-9733-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-015-9733-9</ArticleId><ArticleId IdType="pmc">PMC4406956</ArticleId><ArticleId IdType="pubmed">25758352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ring A., Lang B., Kazaroho C., Labes D., Schall R., and Sch&#xfc;tz H., &#x201c;Sample Size Determination in Bioequivalence Studies Using Statistical Assurance,&#x201d; British Journal of Clinical Pharmacology 85, no. 10 (2019): 2369&#x2013;2377, 10.1111/bcp.14055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14055</ArticleId><ArticleId IdType="pmc">PMC6783617</ArticleId><ArticleId IdType="pubmed">31276603</ArticleId></ArticleIdList></Reference><Reference><Citation>Darken P., DePetrillo P., Reisner C., St Rose E., and Dorinsky P., &#x201c;The Pharmacokinetics of Three Doses of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhaler Compared With Active Controls: A Phase I Randomized, Single&#x2010;Dose, Crossover Study in Healthy Adults,&#x201d; Pulmonary Pharmacology &amp; Therapeutics 50 (2018): 11&#x2013;18, 10.1016/j.pupt.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2018.03.001</ArticleId><ArticleId IdType="pubmed">29544728</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Ye L., Mei J., et&#xa0;al., &#x201c;Pharmacokinetics and Bioequivalence of Two Formulations of Azithromycin Tablets: A Randomized, Single&#x2010;Dose, Three&#x2010;Period, Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions,&#x201d; Drugs in R&amp;D 24, no. 2 (2024): 201&#x2013;209, 10.1007/s40268-024-00464-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40268-024-00464-8</ArticleId><ArticleId IdType="pmc">PMC11315817</ArticleId><ArticleId IdType="pubmed">38811485</ArticleId></ArticleIdList></Reference><Reference><Citation>Metzler C. M., &#x201c;Bioavailability/Bioequivalence: Study Design and Statistical Issues,&#x201d; Journal of Clinical Pharmacology 29, no. 4 (1989): 289&#x2013;292, 10.1002/j.1552-4604.1989.tb03329.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1552-4604.1989.tb03329.x</ArticleId><ArticleId IdType="pubmed">2656773</ArticleId></ArticleIdList></Reference><Reference><Citation>Ar&#x131;soy M., Saydam M., Ekin Dolaks&#x131;z Y., et&#xa0;al., &#x201c;A Study to Compare Bioequivalence Approach Between FDA and EMA in a Highly Variable Drug: Pinaverium Bromide Film Tablets,&#x201d; Journal of Pharmaceutical Sciences 111, no. 11 (2022): 3149&#x2013;3154, 10.1016/j.xphs.2022.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2022.08.010</ArticleId><ArticleId IdType="pubmed">35981633</ArticleId></ArticleIdList></Reference><Reference><Citation>Thacher J. D., Schultz E. S., Hallberg J., et&#xa0;al., &#x201c;Tobacco Smoke Exposure in Early Life and Adolescence in Relation to Lung Function,&#x201d; European Respiratory Journal 51, no. 6 (2018): 1702111, 10.1183/13993003.02111-2017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02111-2017</ArticleId><ArticleId IdType="pmc">PMC6003782</ArticleId><ArticleId IdType="pubmed">29748304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo H., Faiz A., van den Berge M., et&#xa0;al., &#x201c;Cigarette Smoke Exposure Alters Phosphodiesterases in Human Structural Lung Cells,&#x201d; American Journal of Physiology. Lung Cellular and Molecular Physiology 318, no. 1 (2020): L59&#x2013;L64, 10.1152/ajplung.00319.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00319.2019</ArticleId><ArticleId IdType="pubmed">31664853</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim N. Y., Lee C. H., Jin K. N., et&#xa0;al., &#x201c;Clinical Deterioration and Lung Function Change in Patients With Concomitant Asthma and Bronchiectasis,&#x201d; Journal of Allergy and Clinical Immunology. In Practice 10, no. 10 (2022): 2607&#x2013;2613, 10.1016/j.jaip.2022.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaip.2022.05.026</ArticleId><ArticleId IdType="pubmed">35690367</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddel H. K., Bacharier L. B., Bateman E. D., et&#xa0;al., &#x201c;Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes,&#x201d; American Journal of Respiratory and Critical Care Medicine 205, no. 1 (2022): 17&#x2013;35, 10.1164/rccm.202109-2205PP.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202109-2205PP</ArticleId><ArticleId IdType="pmc">PMC8865583</ArticleId><ArticleId IdType="pubmed">34658302</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisfeld L., Shu Y., and Shah T. P., &#x201c;Bioequivalence of Budesonide Plus Formoterol (BF) Spiromax and BF Turbohaler (With and Without Charcoal Block) in Healthy Volunteers,&#x201d; International Journal of Clinical Pharmacology and Therapeutics 53, no. 7 (2015): 593&#x2013;602, 10.5414/CP202238.</Citation><ArticleIdList><ArticleId IdType="doi">10.5414/CP202238</ArticleId><ArticleId IdType="pubmed">26042485</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc7;akmakl&#x131; S., &#xd6;zdemir A., F&#x131;rat H., and Aypak C., &#x201c;An Evaluation of the Use of Inhalers in Asthma and Chronic Obstructive Pulmonary Disease,&#x201d; Journal of Taibah University Medical Sciences 18, no. 4 (2023): 860&#x2013;867, 10.1016/j.jtumed.2023.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtumed.2023.01.001</ArticleId><ArticleId IdType="pmc">PMC9957742</ArticleId><ArticleId IdType="pubmed">36852239</ArticleId></ArticleIdList></Reference><Reference><Citation>
U.S. Food and Drug Administration
, &#x201c;Draft Guidance on Budesonide; Formoterol Fumarate Dihydrate,&#x201d;
https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021929.pdf.</Citation></Reference><Reference><Citation>Dunn L. J., Kerwin E. M., DeAngelis K., Darken P., Gillen M., and Dorinsky P., &#x201c;Pharmacokinetics of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co&#x2010;Suspension Delivery Technology After Single and Chronic Dosing in Patients With COPD,&#x201d; Pulmonary Pharmacology &amp; Therapeutics 60 (2020): 101873, 10.1016/j.pupt.2019.101873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2019.101873</ArticleId><ArticleId IdType="pubmed">31841699</ArticleId></ArticleIdList></Reference><Reference><Citation>Clearie K. L., Williamson P. A., Meldrum K., et&#xa0;al., &#x201c;Pharmacokinetic and Pharmacodynamic Comparison of Hydrofluoroalkane and Chlorofluorocarbon Formulations of Budesonide,&#x201d; British Journal of Clinical Pharmacology 71, no. 4 (2011): 504&#x2013;513, 10.1111/j.1365-2125.2010.03857.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2010.03857.x</ArticleId><ArticleId IdType="pmc">PMC3080637</ArticleId><ArticleId IdType="pubmed">21395643</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillen M., Forte P., Svensson J. O., et&#xa0;al., &#x201c;Effect of a Spacer on Total Systemic and Lung Bioavailability in Healthy Volunteers and In&#xa0;Vitro Performance of the Symbicort (Budesonide/Formoterol) Pressurized Metered Dose Inhaler,&#x201d; Pulmonary Pharmacology &amp; Therapeutics 52 (2018): 7&#x2013;17, 10.1016/j.pupt.2018.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pupt.2018.08.001</ArticleId><ArticleId IdType="pubmed">30077809</ArticleId></ArticleIdList></Reference><Reference><Citation>Tronde A., Gillen M., Borgstr&#xf6;m L., L&#xf6;tvall J., and Ankerst J., &#x201c;Pharmacokinetics of Budesonide and Formoterol Administered via 1 Pressurized Metered&#x2010;Dose Inhaler in Patients With Asthma and COPD,&#x201d; Journal of Clinical Pharmacology 48, no. 11 (2008): 1300&#x2013;1308, 10.1177/0091270008322122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0091270008322122</ArticleId><ArticleId IdType="pubmed">18974284</ArticleId></ArticleIdList></Reference><Reference><Citation>Eedara B. B., Bastola R., and Das S. C., &#x201c;Dissolution and Absorption of Inhaled Drug Particles in the Lungs,&#x201d; Pharmaceutics 14, no. 12 (2022): 2667, 10.3390/pharmaceutics14122667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics14122667</ArticleId><ArticleId IdType="pmc">PMC9781681</ArticleId><ArticleId IdType="pubmed">36559160</ArticleId></ArticleIdList></Reference><Reference><Citation>Nokhodchi A., Chavan S., and Ghafourian T., &#x201c;In Vitro Dissolution and Permeability Testing of Inhalation Products: Challenges and Advances,&#x201d; Pharmaceutics 15, no. 3 (2023): 983, 10.3390/pharmaceutics15030983.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15030983</ArticleId><ArticleId IdType="pmc">PMC10059005</ArticleId><ArticleId IdType="pubmed">36986844</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40936477</PMID><DateCompleted><Year>2026</Year><Month>01</Month><Day>19</Day></DateCompleted><DateRevised><Year>2026</Year><Month>01</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2160-7648</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2026</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical pharmacology in drug development</Title><ISOAbbreviation>Clin Pharmacol Drug Dev</ISOAbbreviation></Journal><ArticleTitle>Comparison of the Pharmacokinetics of Three Budesonide Formulations in Healthy Chinese Subjects.</ArticleTitle><Pagination><StartPage>e1603</StartPage><MedlinePgn>e1603</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpdd.1603</ELocationID><Abstract><AbstractText>HR19042 is a novel, orally administered, targeted-release formulation of the topically active corticosteroid budesonide, developed to release active drug within the terminal ileum and indicated to reduced estimated glomerular filtration rate loss in adults with primary immunoglobulin A nephropathy. This randomized, single-dose, open-label, six-sequence, three-treatment crossover trial aimed to explore the pharmacokinetic (PK) of HR19042 in comparison with two other budesonide targeted-release formulations among healthy Chinese subjects. Plasma budesonide concentrations were measured via liquid chromatography with tandem mass spectrometry, and PK parameters were analyzed using non-compartmental methods. Eighteen subjects successfully completed the trial. The median T<sub>lag</sub> and T<sub>max</sub> of HR19042 were 1.25 and 3.50 h shorter than those of Nefecon, respectively. The C<sub>max</sub> of HR19042 was approximately 1.9-fold higher than that of Nefecon and 1.4-fold higher than that of Budenofalk. Based on the AUC<sub>0-t</sub> determination, the relative bioavailability (F) of HR19042 was approximately 136.93% relative to Nefecon and 129.68% relative to Budenofalk. In vitro, the dissolution of HR19042 occurred 30 min earlier than that of Nefecon in the intestinal buffer medium. In conclusion, both in vivo and in vitro findings suggest that HR19042 exhibits a faster absorption rate and higher oral bioavailability.</AbstractText><CopyrightInformation>&#xa9; 2025, The American College of Clinical Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Tengrui</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zou</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Mengchang</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Qiwen</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Huihui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuyang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yijue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yuanyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Lin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Jiangsu Hengrui Medicine</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Drug Dev</MedlineTA><NlmUniqueID>101572899</NlmUniqueID><ISSNLinking>2160-763X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>51333-22-3</RegistryNumber><NameOfSubstance UI="D019819">Budesonide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Population" UI="C000724312">Chinese people</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019819" MajorTopicYN="Y">Budesonide</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="Y">Glucocorticoids</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N" AutoHM="Y">East Asian People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IgAN</Keyword><Keyword MajorTopicYN="N">budesonide</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">targeted release</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2026</Year><Month>1</Month><Day>19</Day><Hour>12</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>4</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40936477</ArticleId><ArticleId IdType="doi">10.1002/cpdd.1603</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Floege J. The pathogenesis of IgA nephropathy: what is new and how does it change therapeutic approaches? Am J Kidney Dis. 2011;58(6):992&#x2010;1004.</Citation></Reference><Reference><Citation>Barratt J, Rovin BH, Cattran D, et&#xa0;al. Why target the gut to treat IgA nephropathy? Kidney Int Rep. 2020;5(10):1620&#x2010;1624.</Citation></Reference><Reference><Citation>Barratt J, Lafayette RA, Rovin BH, Fellstr&#xf6;m B. Budesonide delayed&#x2010;release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy. Expert Rev Clin Immunol. 2023;19(7):699&#x2010;710.</Citation></Reference><Reference><Citation>Selvaskandan H, Barratt J, Cheung CK. Immunological drivers of IgA nephropathy: exploring the mucosa&#x2013;kidney link. Int J Immunogenet. 2021;49(1):8&#x2010;21.</Citation></Reference><Reference><Citation>Vecchio LD, Rimoldi C, Pozzi C. Nefecon (targeted&#x2010;release formulation&#x2010;budesonide) for the treatment of IgA nephropathy. Future Rare Dis. 2021;1(4). doi:10.2217/frd&#x2010;2021&#x2010;0013</Citation></Reference><Reference><Citation>Lv J, Wong MG, Hladunewich MA, et&#xa0;al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy. JAMA. 2022;327(19):1888&#x2010;1898.</Citation></Reference><Reference><Citation>Rauen T, Eitner F, Fitzner C, et&#xa0;al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225&#x2010;2236.</Citation></Reference><Reference><Citation>Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet. 2004;43 (12):803&#x2010;821.</Citation></Reference><Reference><Citation>Selvaskandan H, Barratt J, Cheung CK. Novel treatment paradigms: primary IgA nephropathy. Kidney Int Rep. 2024;9(2):203&#x2010;213.</Citation></Reference><Reference><Citation>Kinpeygo (budesonide) [European summary of product characteristics]. Bad Vilbel; STADA Arzneimittel AG; 2024. Accessed July 22, 2024. https://www.ema.europa.eu/documents/product&#x2010;information/kinpeygo&#x2010;epar&#x2010;product&#x2010;information_en.pdf</Citation></Reference><Reference><Citation>Tarpeyo (budesonide) [US prescribing information]. Stockholm; Calliditas Therapeutics AB; 2024. Accessed July 22, 2024. https://www.tarpeyo.com/prescribinginformation.pdf</Citation></Reference><Reference><Citation>Barratt J, Lafayette R, Kristensen J, et&#xa0;al. Results from part A of the multi&#x2010;center, double&#x2010;blind, randomized, placebo&#x2010;controlled NefIgArd trial, which evaluated targeted&#x2010;release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103(2):391&#x2010;402.</Citation></Reference><Reference><Citation>Lafayette R, Kristensen J, Stone A, et&#xa0;al. Efficacy and safety of a targeted&#x2010;release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2&#x2010;year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859&#x2010;870.</Citation></Reference><Reference><Citation>Barratt J, Kristensen J, Pedersen C, Jerling M. Insights on Nefecon&#xae;, a targeted&#x2010;release formulation of budesonide and its selective immunomodulatory effects in patients with IgA nephropathy. Drug Des Dev Ther. 2024;18:3415&#x2010;3428.</Citation></Reference><Reference><Citation>Seideg&#xe5;rd J, Nyberg L, Borg&#xe5; O. Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole. Eur J Pharm Sci. 2008;35(4):264&#x2010;270.</Citation></Reference><Reference><Citation>O'Grady J, Murphy CL, Barry L, Shanahan F, Buckley M. Defining gastrointestinal transit time using video capsule endoscopy: a study of healthy subjects. Endosc Int Open. 2020;08(03):E396&#x2010;E400.</Citation></Reference><Reference><Citation>Szarka LA, Camilleri M. Methods for the assessment of small&#x2010;bowel and colonic transit. Semin Nucl Med. 2012;42(2):113&#x2010;123.</Citation></Reference><Reference><Citation>Fellstr&#xf6;m BC, Barratt J, Cook H, et&#xa0;al. Targeted&#x2010;release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double&#x2010;blind, randomised, placebo&#x2010;controlled phase 2b trial. Lancet. 2017;389(10084):2117&#x2010;2127.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39263900</PMID><DateCompleted><Year>2025</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1552-4604</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of clinical pharmacology</Title><ISOAbbreviation>J Clin Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>225</EndPage><MedlinePgn>217-225</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jcph.6131</ELocationID><Abstract><AbstractText>Budesonide oral suspension (BOS) is a swallowed corticosteroid indicated for 12-week therapy in eosinophilic esophagitis with minimal systemic exposure following administration. We aimed to assess the relative bioavailability of a single dose of BOS administered under fasting and fed (high-fat/high-calorie meal) conditions. Healthy adult volunteers (N = 20) were enrolled in an open-label, single-center, crossover study and were randomized (1:1) to receive a single oral dose of BOS 2.0 mg under fasting or fed conditions, with a 48-h washout period before crossover to the alternative conditions. Serial plasma samples were collected before and up to 24 h after dosing. Pharmacokinetic (PK) parameters were calculated from plasma budesonide concentration-time profiles by noncompartmental analysis. The mean peak budesonide concentration (C<sub>max</sub>) was &#x223c;13% lower under fed than under fasting conditions (604.1 vs 692.9 pg/mL). Areas under the concentration-time curves from dosing to the last measurable budesonide concentration and from dosing to infinity were &#x223c;26% higher and &#x223c;27% higher under fed than fasting conditions (3529 vs 2811 pg h/mL and 3892 vs 3075 pg h/mL, respectively). The median time to peak plasma budesonide concentration was significantly longer (&#x223c;1 h) under fed than fasting conditions (2.516 vs 1.286 h, P &lt;&#xa0;.001). Safety and tolerability were also assessed throughout the study; all adverse events were mild or moderate in severity. Despite slight differences in budesonide PK parameters between fed and fasting conditions, the effect of food on systemic exposure to budesonide (BOS formulation) is not expected to be clinically meaningful.</AbstractText><CopyrightInformation>&#xa9; 2024 Takeda Pharmaceuticals USA, Inc. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prokopienko</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Takeda Development Center Americas, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junyao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Takeda Development Center Americas, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yajnik</LastName><ForeName>Vijay</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceuticals USA, Inc., Lexington, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baratta</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Takeda Development Center Americas, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Nirav K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>Takeda Development Center Americas, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richmond</LastName><ForeName>Camilla A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Takeda Development Center Americas, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suri</LastName><ForeName>Ajit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Takeda Development Center Americas, Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Takeda Development Center Americas, Inc.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Clin Pharmacol</MedlineTA><NlmUniqueID>0366372</NlmUniqueID><ISSNLinking>0091-2700</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>51333-22-3</RegistryNumber><NameOfSubstance UI="D019819">Budesonide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013535">Suspensions</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019819" MajorTopicYN="Y">Budesonide</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018565" MajorTopicYN="Y">Food-Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="N">Fasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013535" MajorTopicYN="N">Suspensions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">budesonide oral suspension</Keyword><Keyword MajorTopicYN="N">eosinophilic esophagitis</Keyword><Keyword MajorTopicYN="N">food&#x2010;effect study</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">swallowed corticosteroids</Keyword></KeywordList><CoiStatement>Alexander J. Prokopienko, J.W., Ajit Suri, Mike Baratta, Nirav K. Desai, and Camilla A. Richmond are employees of Takeda Development Center Americas, Inc., and are stockholders of Takeda Pharmaceutical Company Limited. Vijay Yajnik is an employee of Takeda Pharmaceuticals USA, Inc., and is a stockholder of Takeda Pharmaceutical Company Limited.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>12</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>1</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39263900</ArticleId><ArticleId IdType="pmc">PMC11771711</ArticleId><ArticleId IdType="doi">10.1002/jcph.6131</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dellon ES, Liacouras CA, Molina&#x2010;Infante J, et&#xa0;al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022&#x2010;1033.e1010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6174113</ArticleId><ArticleId IdType="pubmed">30009819</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins MH, Dellon ES, Katzka DA, Hirano I, Williams J, Lan L. Budesonide oral suspension significantly improves eosinophilic esophagitis histology scoring system results: analyses from a 12&#x2010;week, phase 2, randomized, placebo&#x2010;controlled trial. Am J Surg Pathol. 2019;43(11):1501&#x2010;1509.</Citation><ArticleIdList><ArticleId IdType="pubmed">31498177</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn JW, Lee K, Shin JI, et&#xa0;al. Global incidence and prevalence of eosinophilic esophagitis, 1976&#x2013;2022: a systematic review and meta&#x2010;analysis. Clin Gastroenterol Hepatol. 2023;21(13):3270&#x2010;3284.e3277.</Citation><ArticleIdList><ArticleId IdType="pubmed">37331411</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rhijn BD, Smout AJ, Bredenoord AJ. Disease duration determines health&#x2010;related quality of life in adult eosinophilic esophagitis patients. Neurogastroenterol Motil. 2014;26(6):772&#x2010;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">24602119</ArticleId></ArticleIdList></Reference><Reference><Citation>Safroneeva E, Coslovsky M, Kuehni CE, et&#xa0;al. Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity. Aliment Pharmacol Ther. 2015;42(8):1000&#x2010;1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">26271642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, Shaheen NJ. Health&#x2010;related quality of life and costs associated with eosinophilic esophagitis: a systematic review. Clin Gastroenterol Hepatol. 2018;16(4):495&#x2010;503.e498.</Citation><ArticleIdList><ArticleId IdType="pubmed">28655543</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuta GT, Katzka DA. Eosinophilic esophagitis. N Engl J Med. 2015;373(17):1640&#x2010;1648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4905697</ArticleId><ArticleId IdType="pubmed">26488694</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossetti D, Isoldi S, Oliva S. Eosinophilic esophagitis: update on diagnosis and treatment in pediatric patients. Paediatr Drugs. 2020;22(4):343&#x2010;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">32519266</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano I, Chan ES, Rank MA, et&#xa0;al. AGA institute and the joint task force on allergy&#x2010;immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterology. 2020;158(6):1776&#x2010;1786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9473154</ArticleId><ArticleId IdType="pubmed">32359562</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougherty T, Jr. , Stephen S, Borum ML, Doman DB. Emerging therapeutic options for eosinophilic esophagitis. Gastroenterol Hepatol (N Y). 2014;10(2):106&#x2010;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011375</ArticleId><ArticleId IdType="pubmed">24803874</ArticleId></ArticleIdList></Reference><Reference><Citation>
Takeda Pharmaceuticals America Inc
. Highlights of prescribing information, EOHILIA 2024. US FDA. Accessed May 31, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213976s000lbl.pdf
</Citation></Reference><Reference><Citation>Dellon ES, Katzka DA, Collins MH, et&#xa0;al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. Gastroenterology. 2017;152(4):776&#x2010;786.e775.</Citation><ArticleIdList><ArticleId IdType="pubmed">27889574</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano I, Dellon ES, Gupta SK, et&#xa0;al. Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1&#x2013;3 clinical trials. Aliment Pharmacol Ther. 2023;57(10):1117&#x2010;1130.</Citation><ArticleIdList><ArticleId IdType="pubmed">36890134</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed CC, Fan C, Koutlas N, et&#xa0;al. Compounded oral viscous budesonide is effective and provides a durable response in eosinophilic esophagitis. HSOA J Gastroenterol Hepatol Res. 2018;7(1):2509&#x2010;2515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5875939</ArticleId><ArticleId IdType="pubmed">29608193</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta SK, Hill M, Vitanza JM, et&#xa0;al. Pharmacokinetics of budesonide oral suspension in children and adolescents with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2022;75(2):186&#x2010;191.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9278710</ArticleId><ArticleId IdType="pubmed">35666852</ArticleId></ArticleIdList></Reference><Reference><Citation>Song IH, Finkelman RD, Lan L. A pharmacokinetic bridging study to compare systemic exposure to budesonide between budesonide oral suspension and ENTOCORT EC in healthy individuals. Drugs R D. 2020;20(4):359&#x2010;367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691405</ArticleId><ArticleId IdType="pubmed">33057953</ArticleId></ArticleIdList></Reference><Reference><Citation>Song IH, Rodgers T, Hayes S, Farrell C. A population pharmacokinetic analysis of budesonide oral suspension in children and adults with eosinophilic esophagitis and healthy adult volunteers. Am J Gastroenterol. 2020;115:S220.</Citation></Reference><Reference><Citation>Lundin P, Naber T, Nilsson M, Edsbacker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease. Aliment Pharmacol Ther. 2001;15(1):45&#x2010;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11136277</ArticleId></ArticleIdList></Reference><Reference><Citation>Edsbacker S, Bengtsson B, Larsson P, et&#xa0;al. A pharmacoscintigraphic evaluation of oral budesonide given as controlled&#x2010;release (Entocort) capsules. Aliment Pharmacol Ther. 2003;17(4):525&#x2010;536.</Citation><ArticleIdList><ArticleId IdType="pubmed">12622761</ArticleId></ArticleIdList></Reference><Reference><Citation>
Salix Pharmaceuticals, Inc., a division of Bausch Health US, LLC
. Uceris&#xae; (budesonide) extended&#x2010;release tablets. Prescribing information. 2020. Accessed May 31, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203634s007lbl.pdf
</Citation></Reference><Reference><Citation>
AstraZeneca
. Entocort EC (budesonide) delayed&#x2010;release capsules. Prescribing information. 2020. Accessed May 31, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021324s023lbl.pdf
</Citation></Reference><Reference><Citation>
US Food and Drug Administration
. Assessing the effects of food on drugs in INDs and NDAs &#x2014; clinical pharmacology considerations. Guidance for industry. 2022. Accessed May 31, 2024. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070241.pdf
</Citation></Reference><Reference><Citation>
ClinicalTrials.gov
. An extension study to evaluate maintenance of efficacy and long&#x2010;term treatment effect of oral budesonide suspension (OBS) in adults and adolescents with eosinophilic esophagitis (EoE) (ORBIT2). Accessed May 31, 2024. https://www.clinicaltrials.gov/study/NCT02736409
</Citation></Reference><Reference><Citation>
ClinicalTrials.gov
. Continuation study with budesonide oral suspension (BOS) for adolescent and adult subjects with eosinophilic esophagitis (EoE). Accessed May 31, 2024. https://clinicaltrials.gov/ct2/show/study/NCT03245840
</Citation></Reference><Reference><Citation>Glowczewski A, Krogulska A. Formulations of topical steroids in eosinophilic esophagitis &#x2010; current treatment and emerging possibilities. J Clin Med. 2022;11(5):1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8910832</ArticleId><ArticleId IdType="pubmed">35268544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano I, Collins MH, Katzka DA, et&#xa0;al. Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial. Clin Gastroenterol Hepatol. 2022;20(3):525&#x2010;534.e510.</Citation><ArticleIdList><ArticleId IdType="pubmed">33887475</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinther S, Christensen M, Christensen HR. The importance of convenience for patient adherence to drug treatments &#x2010; an overview of secondary literature. Clin Ther. 2015;37(8):E95&#x2010;E96.</Citation></Reference><Reference><Citation>Haasnoot ML, Safi S, Bredenoord AJ. Poor adherence to medical and dietary treatments in adult patients with eosinophilic esophagitis. Am J Gastroenterol. 2022;117(9):1412&#x2010;1418.</Citation><ArticleIdList><ArticleId IdType="pubmed">35973155</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander R, Alexander JA, Ravi K, et&#xa0;al. Measurement of observed eating behaviors in patients with active and inactive eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17(11):2371&#x2010;2373.</Citation><ArticleIdList><ArticleId IdType="pubmed">30557737</ArticleId></ArticleIdList></Reference><Reference><Citation>
ClinicalTrials.gov
. A study in adolescents and adults with eosinophilic esophagitis (EoE) measuring histologic response and determine if reduction in dysphagia is achieved (NCT02605867). Accessed May 31, 2024. https://classic.clinicaltrials.gov/ct2/show/NCT02605837
</Citation></Reference><Reference><Citation>Comer GM, Bush MA, Dellon ES, Marino MT. Effect of food intake and body position on the pharmacokinetics of swallowed APT&#x2010;1011, a fluticasone orally disintegrating tablet, in healthy adult volunteers. J Clin Pharmacol. 2020;60(6):734&#x2010;743.</Citation><ArticleIdList><ArticleId IdType="pubmed">31943257</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellon ES, Collins MH, Katzka DA, et&#xa0;al. Long&#x2010;term treatment of eosinophilic esophagitis with budesonide oral suspension. Clin Gastroenterol Hepatol. 2022;20(7):1488&#x2010;1498.e1411.</Citation><ArticleIdList><ArticleId IdType="pubmed">34182150</ArticleId></ArticleIdList></Reference><Reference><Citation>Dellon ES, Katzka DA, Collins MH, et&#xa0;al. Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019;17(4):666&#x2010;673.e668.</Citation><ArticleIdList><ArticleId IdType="pubmed">29902649</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2015;13(1):66&#x2010;76.e63.</Citation><ArticleIdList><ArticleId IdType="pubmed">24907502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim AW, Talley NJ, Walker MM, Storm G, Hua S. Current status and advances in esophageal drug delivery technology: influence of physiological, pathophysiological and pharmaceutical factors. Drug Deliv. 2023;30(1):2219423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10286676</ArticleId><ArticleId IdType="pubmed">37344759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37765205</PMID><DateRevised><Year>2023</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>30</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn's Disease Patients through PBPK Modeling.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2237</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics15092237</ELocationID><Abstract><AbstractText>The most common method for establishing bioequivalence (BE) is to demonstrate similarity of concentration-time profiles in the systemic circulation, as a surrogate to the site of action. However, similarity of profiles from two formulations in the systemic circulation does not imply similarity in the gastrointestinal tract (GIT) nor local BE. We have explored the concordance of BE conclusions for a set of hypothetical formulations based on budesonide concentration profiles in various segments of gut vs. those in systemic circulation using virtual trials powered by physiologically based pharmacokinetic (PBPK) models. The impact of Crohn's disease on the BE conclusions was explored by changing physiological and biological GIT attributes. Substantial 'discordance' between local and systemic outcomes of VBE was observed. Upper GIT segments were much more sensitive to formulation changes than systemic circulation, where the latter led to false conclusions for BE. The ileum and colon showed a lower frequency of discordance. In the case of Crohn's disease, a product-specific similarity factor might be needed for products such as Entocort<sup>&#xae;</sup> EC to ensure local BE. Our results are specific to budesonide, but we demonstrate potential discordances between the local gut vs. systemic BE for the first time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Chunyan</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0007-7304-0336</Identifier><AffiliationInfo><Affiliation>Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, Manchester M13 9PL, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaron Inc., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Tiancheng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Pharmaron Inc., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chirumamilla</LastName><ForeName>Siri Kalyan</ForeName><Initials>SK</Initials><Identifier Source="ORCID">0000-0002-5026-8369</Identifier><AffiliationInfo><Affiliation>Simcyp Division, Certara, Sheffield S1 2BJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bois</LastName><ForeName>Frederic Y</ForeName><Initials>FY</Initials><Identifier Source="ORCID">0000-0002-4154-0391</Identifier><AffiliationInfo><Affiliation>Simcyp Division, Certara, Sheffield S1 2BJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Mandy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaron Inc., Beijing 100176, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rostami-Hodjegan</LastName><ForeName>Amin</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3917-844X</Identifier><AffiliationInfo><Affiliation>Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, Manchester M13 9PL, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Simcyp Division, Certara, Sheffield S1 2BJ, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Entocort EC</Keyword><Keyword MajorTopicYN="N">f2</Keyword><Keyword MajorTopicYN="N">gut-wall exposure</Keyword><Keyword MajorTopicYN="N">local BE</Keyword><Keyword MajorTopicYN="N">local bioequivalence</Keyword><Keyword MajorTopicYN="N">virtual bioequivalence</Keyword></KeywordList><CoiStatement>C.H., T.S. and M.X. are employees of Pharmaron Inc., an R&amp;D service provider for the life sciences industry. S.C., F.Y.B. and A.R.H. are employees of Certara Ltd., a provider of modeling and simulation platforms in the quantitative systems pharmacology sector to academic and industrial institutions. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37765205</ArticleId><ArticleId IdType="pmc">PMC10535222</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics15092237</ArticleId><ArticleId IdType="pii">pharmaceutics15092237</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yu L.X., Li B.V. FDA Bioequivalence Standards. Springer; New York, NY, USA: 2014.</Citation></Reference><Reference><Citation>CFR . Codes of Federal Regulations. CFR; New York, NY, USA: 2021. Chapter 21, Part 314.</Citation></Reference><Reference><Citation>Amidon G.L. Bioequivalence Testing for Locally Acting Gastrointestinal Drugs: Scientific Principles; Proceedings of the FDA Meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Rockville, MD, USA. 14 April 2004.</Citation></Reference><Reference><Citation>Olivares-Morales A., Kamiyama Y., Darwich A.S., Aarons L., Rostami-Hodjegan A. Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. Eur. J. Pharm. Sci. 2015;67:32&#x2013;44. doi: 10.1016/j.ejps.2014.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2014.10.018</ArticleId><ArticleId IdType="pubmed">25444842</ArticleId></ArticleIdList></Reference><Reference><Citation>Loisios-Konstantinidis I., Cristofoletti R., Fotaki N., Turner D.B., Dressman J. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen. Eur. J. Pharm. Sci. 2020;143:105170. doi: 10.1016/j.ejps.2019.105170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2019.105170</ArticleId><ArticleId IdType="pubmed">31783158</ArticleId></ArticleIdList></Reference><Reference><Citation>DrugBank Online.  [(accessed on 12 April 2022)].  Available online:  https://go.drugbank.com/drugs/DB01222.</Citation></Reference><Reference><Citation>Nunes T., Acosta M.B., Marin-Jim&#xe9;nez I., Nos P., Sans M. Oral locally active steroids in inflammatory bowel disease. J. Crohn&#x2019;s Colitis. 2013;7:183&#x2013;191. doi: 10.1016/j.crohns.2012.06.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crohns.2012.06.010</ArticleId><ArticleId IdType="pubmed">22784947</ArticleId></ArticleIdList></Reference><Reference><Citation>Edsb&#xe4;cker S., Andersson T. Pharmacokinetics of budesonide (Entocort&#x2122; EC) capsules for Crohn&#x2019;s disease. Clin. Pharmacokinet. 2004;43:803&#x2013;821.</Citation><ArticleIdList><ArticleId IdType="pubmed">15355126</ArticleId></ArticleIdList></Reference><Reference><Citation>Wikberg M., Ulmius J., Ragnarsson G. Review article: Targeted drug delivery in treatment of intestinal diseases. Aliment. Pharmacol. Ther. 1997;11:109&#x2013;115. doi: 10.1111/j.1365-2036.1997.tb00815.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.1997.tb00815.x</ArticleId><ArticleId IdType="pubmed">9467985</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorsson L., Edsb&#xe4;cker S., Conradson T.B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur. Respir. J. 1994;7:1839&#x2013;1844. doi: 10.1183/09031936.94.07101839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.94.07101839</ArticleId><ArticleId IdType="pubmed">7828694</ArticleId></ArticleIdList></Reference><Reference><Citation>Seideg&#xe5;rd J., Nyberg L., Borg&#xe5; O. Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole. Eur. J. Pharm. Sci. 2008;35:264&#x2013;270. doi: 10.1016/j.ejps.2008.07.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2008.07.005</ArticleId><ArticleId IdType="pubmed">18706998</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilger K., Halter J.R., Bertz H., Lopez-Lazaro L., Gratwohl A., Finke J.R. Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease. Biol. Blood Marrow Transplant. 2009;15:336&#x2013;343. doi: 10.1016/j.bbmt.2008.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbmt.2008.12.001</ArticleId><ArticleId IdType="pubmed">19203724</ArticleId></ArticleIdList></Reference><Reference><Citation>Edsb&#xe4;cker S., Bengtsson B., Larsson P., Lundin P., Nilsson &#xc5;., Ulmius J., Wollmer P. A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules. Aliment. Pharmacol. Ther. 2003;17:525&#x2013;536. doi: 10.1046/j.1365-2036.2003.01426.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01426.x</ArticleId><ArticleId IdType="pubmed">12622761</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA . New Drug Application Entocort (21-324): Clinical Pharmacology and Biopharmaceutics Review. FDA; Silver Spring, MD, USA: 2000.</Citation></Reference><Reference><Citation>Lundin P.D.P., Edsb&#xe4;cker S., Bergstrand M., Ejderhamn J., Linander H., H&#xf6;gberg L., Persson T., Escher J.C., Lindquist B. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn&#x2019;s disease. Aliment. Pharmacol. Ther. 2003;17:85&#x2013;92. doi: 10.1046/j.1365-2036.2003.01386.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01386.x</ArticleId><ArticleId IdType="pubmed">12492736</ArticleId></ArticleIdList></Reference><Reference><Citation>Edsb&#xe4;cker S., Larsson P., Bergstrand M. Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole. Aliment. Pharmacol. Ther. 2003;17:403&#x2013;408. doi: 10.1046/j.1365-2036.2003.01431.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01431.x</ArticleId><ArticleId IdType="pubmed">12562453</ArticleId></ArticleIdList></Reference><Reference><Citation>Seideg&#xe5;rd J. Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration. Clin. Pharmacol. Ther. 2000;68:13&#x2013;17. doi: 10.1067/mcp.2000.106895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mcp.2000.106895</ArticleId><ArticleId IdType="pubmed">10945311</ArticleId></ArticleIdList></Reference><Reference><Citation>Seideg&#xe5;rd J., Simonsson M., Edsb&#xe4;cker S. Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol. Clin. Pharmacol. Ther. 2000;67:373&#x2013;381. doi: 10.1067/mcp.2000.105762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mcp.2000.105762</ArticleId><ArticleId IdType="pubmed">10801246</ArticleId></ArticleIdList></Reference><Reference><Citation>Seideg&#xe5;rd J., Randvall G., Nyberg L., Borga O. Grapefruit juice interaction with oral budesonide: Equal effect on immediate-release and delayed-release formulations. Pharmazie. 2009;64:461&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">19694184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundin P., Naber T., Nilsson M., Edsb&#xe4;cker S. Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn&#x2019;s disease. Aliment. Pharmacol. Ther. 2001;15:45&#x2013;51. doi: 10.1046/j.1365-2036.2001.00910.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2001.00910.x</ArticleId><ArticleId IdType="pubmed">11136277</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson A., Tirona R.G., Kim R.B. CYP3A4 activity is markedly lower in patients with Crohn&#x2019;s disease. Inflamm. Bowel Dis. 2017;23:804&#x2013;813. doi: 10.1097/MIB.0000000000001062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MIB.0000000000001062</ArticleId><ArticleId IdType="pubmed">28301431</ArticleId></ArticleIdList></Reference><Reference><Citation>Effinger A., O&#x2019;Driscoll C.M., McAllister M., Fotaki N. Predicting budesonide performance in healthy subjects and patients with Crohn&#x2019;s disease using biorelevant in vitro dissolution testing and PBPK modeling. Eur. J. Pharm. Sci. 2021;157:105617. doi: 10.1016/j.ejps.2020.105617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2020.105617</ArticleId><ArticleId IdType="pubmed">33164838</ArticleId></ArticleIdList></Reference><Reference><Citation>Alrubia S., Mao J., Chen Y., Barber J., Rostami-Hodjegan A. Altered bioavailability and pharmacokinetics in Crohn&#x2019;s disease: Capturing systems parameters for PBPK to assist with predicting the fate of orally administered drugs. Clin. Pharmacokinet. 2022;61:1365&#x2013;1392. doi: 10.1007/s40262-022-01169-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-022-01169-4</ArticleId><ArticleId IdType="pmc">PMC9553790</ArticleId><ArticleId IdType="pubmed">36056298</ArticleId></ArticleIdList></Reference><Reference><Citation>Fagerberg J.H., Sj&#xf6;gren E., Bergstr&#xf6;m C.A.S. Concomitant intake of alcohol may increase the absorption of poorly soluble drugs. Eur. J. Pharm. Sci. 2015;67:12&#x2013;20. doi: 10.1016/j.ejps.2014.10.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2014.10.017</ArticleId><ArticleId IdType="pubmed">25444841</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson G.M., Orrego H., Israel Y., Devenyi P., Kapur B.M. Low-molecular-weight polyethylene glycol as a probe of gastrointestinal permeability after alcohol ingestion. Dig. Dis. Sci. 1981;26:971&#x2013;977. doi: 10.1007/BF01314757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01314757</ArticleId><ArticleId IdType="pubmed">7297377</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Huo M., Zhou J., Zou A., Li W., Yao C., Xie S. DDSolver: An add-In program for modeling and comparison of drug dissolution profiles. AAPS J. 2010;12:263&#x2013;271. doi: 10.1208/s12248-010-9185-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-010-9185-1</ArticleId><ArticleId IdType="pmc">PMC2895453</ArticleId><ArticleId IdType="pubmed">20373062</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA . SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. FDA; Silver Spring, MD, USA: 1995.</Citation></Reference><Reference><Citation>Alrubia S., Al-Majdoub Z.M., Achour B., Rostami-Hodjegan A., Barber J. Quantitative assessment of the impact of Crohn&#x2019;s disease on protein abundance of human intestinal drug-metabolising enzymes and transporters. J. Pharm. Sci. 2022;111:2917&#x2013;2929. doi: 10.1016/j.xphs.2022.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xphs.2022.07.012</ArticleId><ArticleId IdType="pubmed">35872023</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA . Draft Guidance on Budesonide. FDA; Silver Spring, MD, USA: 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37607661</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1522-9629</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Pulmonary pharmacology &amp; therapeutics</Title><ISOAbbreviation>Pulm Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential.</ArticleTitle><Pagination><StartPage>102245</StartPage><MedlinePgn>102245</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pupt.2023.102245</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1094-5539(23)00057-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The climate crisis poses an immediate threat to human health and well-being, demanding urgent adaptions across sectors, including healthcare. The development of pressurized metered dose inhalers (MDIs) with greater sensitivity to the climate emergency using novel propellants with lower global warming potentials (GWPs), but comparable pharmacokinetic (PK) parameters to currently marketed MDIs, is a vital step toward reducing the impact of healthcare for respiratory disorders on climate change. This study evaluated the relative bioavailabilities of the individual components of a fixed-dose combination of budesonide/glycopyrrolate/formoterol fumarate (BGF) 160/9/4.8&#xa0;&#x3bc;g per actuation between three different propellant formulations.</AbstractText><AbstractText Label="METHODS">Healthy male participants (aged 18-60 years) were randomized into a single-blind, three-period, single-dose, single-center, crossover study (NCT04600505). The PK and safety and tolerability profiles of BGF MDI formulated with two novel propellants with low GWP (hydrofluoroolefin-1234ze [HFO]; hydrofluorocarbon-152a [HFC]) were compared with BGF MDI formulated with the propellant used in the currently marketed reference product (hydrofluoroalkane-134a [HFA]). The study included a screening period, three treatment periods (with 3- to 7-day washout periods between each dose), and a follow-up. The primary PK parameters assessed were maximum observed plasma concentration (C<sub>max</sub>), area under the plasma concentration curve (AUC) from time zero extrapolated to infinity (AUC<sub>inf</sub>), and AUC from time zero to the time of the last quantifiable analyte concentration (AUC<sub>last</sub>). The study was not powered to statistically demonstrate bioequivalence.</AbstractText><AbstractText Label="RESULTS">Forty-seven participants completed the study, and 24 participants were evaluable for PK assessments. Systemic exposure, based on geometric mean ratios (90% confidence interval), to each BGF component from the test propellants delivered in a standard MDI was comparable with the reference propellant for AUC<sub>last</sub> (HFO vs. HFA: budesonide, 107.30 [94.53, 121.90]; glycopyrrolate, 106.10 [86.18, 130.60]; formoterol, 98.13 [86.44, 111.40]; HFC vs. HFA: budesonide, 98.80 [84.59, 115.40]; glycopyrrolate, 99.71 [80.84, 123.00]; formoterol, 107.00 [88.82, 128.90]); AUC<sub>inf</sub> (where evaluable) and C<sub>max</sub> followed the same trend. There were no serious adverse events or adverse events leading to treatment discontinuation. No new safety signals were observed.</AbstractText><AbstractText Label="CONCLUSIONS">Systemic BGF component exposure was similar for both test propellants (HFO and HFC) compared with the HFA reference propellant, with an acceptable safety profile in the studied population. Therefore, both novel low GWP propellants show strong potential as candidates for development of MDIs with greater sensitivity to the climate crisis, a vital step toward ameliorating the detrimental impact of healthcare on the environment. Further investigation in larger studies is warranted.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aurivillius</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AstraZeneca AB, Gothenburg, Sweden. Electronic address: magnus.aurivillius@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bednarczyk</LastName><ForeName>Artur</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AstraZeneca Pharma Poland, Warsaw, Poland. Electronic address: Artur.Bednarczyk@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokot</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AstraZeneca Pharma Poland, Warsaw, Poland. Electronic address: marek.kokot@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madriaga</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>AstraZeneca Canada, Mississauga, Canada. Electronic address: jonathan.madriaga@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>AstraZeneca AB, Gothenburg, Sweden. Electronic address: Jie.Mei@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collison</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AstraZeneca, Durham, NC, USA. Electronic address: kathryn.collison@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surujbally</LastName><ForeName>Raulin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>StraZeneca, Cambridge, UK. Electronic address: raulin.surujbally@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Archbell</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>AstraZeneca, South San Francisco, CA, USA. Electronic address: james.archbell@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joshi</LastName><ForeName>Vidya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>AstraZeneca, South San Francisco, CA, USA. Electronic address: vidya.joshi@astrazeneca.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gillen</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Creek Lane PK, LLC, Waterford, VA, USA. Electronic address: Michael.Gillen@astrazeneca.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04600505</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pulm Pharmacol Ther</MedlineTA><NlmUniqueID>9715279</NlmUniqueID><ISSNLinking>1094-5539</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>51333-22-3</RegistryNumber><NameOfSubstance UI="D019819">Budesonide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>W34SHF8J2K</RegistryNumber><NameOfSubstance UI="D000068759">Formoterol Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>V92SO9WP2I</RegistryNumber><NameOfSubstance UI="D006024">Glycopyrrolate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001993" MajorTopicYN="Y">Bronchodilator Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019819" MajorTopicYN="N">Budesonide</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068759" MajorTopicYN="N">Formoterol Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057232" MajorTopicYN="N">Global Warming</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006024" MajorTopicYN="Y">Glycopyrrolate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036501" MajorTopicYN="N">Metered Dose Inhalers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioavailability</Keyword><Keyword MajorTopicYN="N">Budesonide/glycopyrrolate/formoterol fumarate</Keyword><Keyword MajorTopicYN="N">Environmental impact</Keyword><Keyword MajorTopicYN="N">Low global warming potential propellant formulation</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics</Keyword><Keyword MajorTopicYN="N">Pressurized metered dose inhaler</Keyword></KeywordList><CoiStatement>Declaration of competing interest MA, AB, MK, JMa, JMe, KC, RS, JA, and VJ are employees of AstraZeneca and hold stock and/or stock options in the company. MG was a contract employee of AstraZeneca at the time this research was conducted and holds stock in the company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>22</Day><Hour>19</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37607661</ArticleId><ArticleId IdType="doi">10.1016/j.pupt.2023.102245</ArticleId><ArticleId IdType="pii">S1094-5539(23)00057-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35815354</PMID><DateCompleted><Year>2022</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1753-4666</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><PubDate><Year>2022</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Therapeutic advances in respiratory disease</Title><ISOAbbreviation>Ther Adv Respir Dis</ISOAbbreviation></Journal><ArticleTitle>Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two different devices on lung function in patients with COPD and low peak inspiratory flow.</ArticleTitle><Pagination><StartPage>17534666221107312</StartPage><MedlinePgn>17534666221107312</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">17534666221107312</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1177/17534666221107312</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS">Low peak inspiratory flow (PIF) is common following severe exacerbations of chronic obstructive pulmonary disease (COPD). Patients with COPD and low PIF may be at risk of suboptimal delivery of inhaled therapies to the airways, especially when using devices such as dry powder inhalers (DPIs), which require greater inspiratory effort than metered dose inhalers (MDIs). We report the results from a 2-week crossover study evaluating the effects of inhaled dual therapy with budesonide/formoterol fumarate dihydrate with an MDI with a spacer <i>versus</i> a DPI in patients with COPD and low PIF.</AbstractText><AbstractText Label="METHODS">This randomized, open-label, two-period (each 1&#x2009;week in duration) crossover efficacy and safety study included patients with severe-to-very severe COPD and PIF&#x2009;&lt;&#x2009;50&#x2009;L/min (NCT04078126). Patients were randomized 1:1 to twice-daily budesonide/formoterol fumarate dihydrate MDI (BFF MDI) 320/10&#x2009;&#xb5;g with a spacer for 1&#x2009;week followed by twice-daily budesonide/formoterol fumarate dihydrate DPI (BUD/FORM DPI) 320/9&#x2009;&#xb5;g for 1&#x2009;week, or the inverse. The primary endpoint was peak change from baseline in forced expiratory volume in 1&#x2009;s (FEV<sub>1</sub>) within 4&#x2009;h post-dose following 1&#x2009;week of treatment. Other assessments included pre-dose lung function, pharmacokinetics, and safety, as assessed by adverse events.</AbstractText><AbstractText Label="RESULTS">The modified intention-to-treat analysis set comprised 30 patients (mean age: 66.9&#x2009;years; mean baseline FEV<sub>1</sub>: 766&#x2009;mL; mean COPD assessment test score: 22.20). Following 1&#x2009;week of treatment, both BFF MDI and BUD/FORM DPI improved mean [95% confidence interval (CI)] peak FEV<sub>1</sub> 4&#x2009;h post-dose [256 (190, 322)&#x2009;mL and 274 (208, 340)&#x2009;mL, respectively]. No clinically meaningful difference between treatments was observed for any lung function endpoint. There were no unexpected safety findings.</AbstractText><AbstractText Label="CONCLUSION">Dual therapy with BFF MDI and with BUD/FORM DPI led to improvements in lung function in patients with severe-to-very severe COPD and low PIF.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huber</LastName><ForeName>B&#xe4;rbel</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical Unit, Inamed GmbH, Gauting, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>Claus</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Lung and Bronchial Medicine, Praxis Dr. Claus Keller, Frankfurt, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenkins</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Late Respiratory and Immunology Biometrics, AstraZeneca, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raza</LastName><ForeName>Abid</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medsearch UK Limited, Slough, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aurivillius</LastName><ForeName>Magnus</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4660-5040</Identifier><AffiliationInfo><Affiliation>AstraZeneca Research and Development, Pepparedsleden 1, Gothenburg 43183, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04078126</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ther Adv Respir Dis</MedlineTA><NlmUniqueID>101316317</NlmUniqueID><ISSNLinking>1753-4658</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>51333-22-3</RegistryNumber><NameOfSubstance UI="D019819">Budesonide</NameOfSubstance></Chemical><Chemical><RegistryNumber>V92SO9WP2I</RegistryNumber><NameOfSubstance UI="D006024">Glycopyrrolate</NameOfSubstance></Chemical><Chemical><RegistryNumber>W34SHF8J2K</RegistryNumber><NameOfSubstance UI="D000068759">Formoterol Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019819" MajorTopicYN="N">Budesonide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068759" MajorTopicYN="N">Formoterol Fumarate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006024" MajorTopicYN="Y">Glycopyrrolate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="Y">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">budesonide</Keyword><Keyword MajorTopicYN="N">chronic obstructive pulmonary disease</Keyword><Keyword MajorTopicYN="N">dry powder inhaler</Keyword><Keyword MajorTopicYN="N">formoterol fumarate dihydrate</Keyword><Keyword MajorTopicYN="N">inhaled dual therapy</Keyword><Keyword MajorTopicYN="N">metered dose inhaler</Keyword><Keyword MajorTopicYN="N">peak inspiratory flow</Keyword></KeywordList><CoiStatement><b>Conflict of interest statement:</b> The authors declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: B.H. is an
employee of Inamed Gmbh (part of Nuvisan Gmbh), which was contracted by
AstraZeneca for this study. C.K. has a lung and bronchial medicine practice,
including a study center in Frankfurt am Main, Germany and was contracted by
AstraZeneca as a consultant research physician for this study. A.R. is an
employee of Medsearch UK Limited and was contracted by AstraZeneca as a
consultant research physician for this study. M.A. and M.J. are employees of
AstraZeneca and own stock or stock options in the company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>7</Month><Day>11</Day><Hour>4</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>7</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35815354</ArticleId><ArticleId IdType="pmc">PMC9340410</ArticleId><ArticleId IdType="doi">10.1177/17534666221107312</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Global Initiative for Chronic Obstructive Lung Disease.
Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease. 2021. 
Report. https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf.</Citation></Reference><Reference><Citation>Sharma G, Mahler DA, Mayorga VM, et al. Prevalence of low peak inspiratory flow rate at discharge in patients hospitalized for COPD exacerbation. Chronic Obstr Pulm Dis 2017; 4: 217&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556913</ArticleId><ArticleId IdType="pubmed">28848933</ArticleId></ArticleIdList></Reference><Reference><Citation>Loh CH, Peters SP, Lovings TM, et al. Suboptimal inspiratory flow rates are associated with chronic obstructive pulmonary disease and all-cause readmissions. Ann Am Thorac Soc 2017; 14: 1305&#x2013;1311.</Citation><ArticleIdList><ArticleId IdType="pubmed">28406710</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc 2017; 14: 1103&#x2013;1107.</Citation><ArticleIdList><ArticleId IdType="pubmed">28481631</ArticleId></ArticleIdList></Reference><Reference><Citation>Feddah MR, Brown KF, Gipps EM, et al. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharmaceut Sci 2000; 3: 318&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">11177650</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman P, Wehbe L, Dederichs J, et al. Comparison of peak inspiratory flow rate via the Breezhaler&#xae;, Ellipta&#xae; and HandiHaler&#xae; dry powder inhalers in patients with moderate to very severe COPD: a randomized cross-over trial. BMC Pulm Med 2018; 18: 100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6001060</ArticleId><ArticleId IdType="pubmed">29898702</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincken W, Levy ML, Scullion J, et al. Spacer devices for inhaled therapy: why use them, and how? ERJ Open Res 2018; 4: 00065-02018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6004521</ArticleId><ArticleId IdType="pubmed">29928649</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorinsky P, DePetrillo P, DeAngelis K, et al. Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate dihydrate metered dose inhaler administered with and without a spacer: results of a phase I, randomized, crossover trial in healthy adults. Clin Ther 2020; 42: 634&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">32253054</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillen M, Forte P, Svensson JO, et al. Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort&#xae; (budesonide/formoterol) pressurized metered dose inhaler. Pulm Pharmacol Ther 2018; 52: 7&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">30077809</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn LJ, Kerwin EM, DeAngelis K, et al. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD. Pulm Pharmacol Ther 2020; 60: 101873.</Citation><ArticleIdList><ArticleId IdType="pubmed">31841699</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson GT, Rabe KF, Martinez FJ, et al. KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD. Eur Respir J 2018; 52(Suppl. 62): OA1661.</Citation></Reference><Reference><Citation>Ferguson G, Rabe K, Bourne E, et al. 12-hour lung function assessment of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler delivered by co-suspension delivery technology in patients with COPD. Presented at the American Thoracic Society 2019 International Conference (May 17&#x2013;22; Dallas, TX, USA), Poster number 540.</Citation></Reference><Reference><Citation>Maes A, DePetrillo P, Siddiqui S, et al. Pharmacokinetics of co-suspension delivery technology budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF MDI) and budesonide/formoterol fumarate dihydrate (BFF MDI) fixed-dose combinations compared with an active control: a Phase 1, randomized, single dose, crossover study in healthy adults. Clin Pharmacol Drug Dev 2019; 8: 223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6585691</ArticleId><ArticleId IdType="pubmed">29901860</ArticleId></ArticleIdList></Reference><Reference><Citation>Samarghandi A, Ioachimescu OC, Qayyum R. Association between peak inspiratory flow rate and hand grip muscle strength in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease. PLOS ONE 2020; 15: e0227737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6994102</ArticleId><ArticleId IdType="pubmed">32004333</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohannon RW. Grip strength: an indispensable biomarker for older adults. Clin Interv Aging 2019; 14: 1681&#x2013;1691.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778477</ArticleId><ArticleId IdType="pubmed">31631989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34783456</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2160-7648</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Clinical pharmacology in drug development</Title><ISOAbbreviation>Clin Pharmacol Drug Dev</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetics and Bioequivalence of a Generic and a Branded Budesonide Nasal Spray in Healthy Chinese Subjects.</ArticleTitle><Pagination><StartPage>516</StartPage><EndPage>522</EndPage><MedlinePgn>516-522</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpdd.1036</ELocationID><Abstract><AbstractText>The aim of this study was to evaluate the pharmacokinetic bioequivalence of a generic budesonide nasal spray and a branded product in healthy Chinese subjects under fasting condition. A single-center, single-dose, randomized, open-label, crossover study was conducted in 32 healthy Chinese subjects under fasting condition. The subjects were administered 256 &#x3bc;g of generic budesonide nasal spray (test drug) or branded budesonide nasal spray (RHINOCORT AQUA, reference drug), respectively. For each period, the subjects were administered with 64 &#x3bc;g of budesonide per spray and 2 sprays for each nostril followed by a washout period of 7 days. Plasma concentration of budesonide was determined by a validated high-performance liquid chromatography-tandem mass spectrometry method. The pharmacokinetic (PK) parameters were calculated, and the bioequivalence was compared using the noncompartment model with the Phoenix WinNonlin 7.0 program. Results show that the 90% confidence intervals of the test/reference ratios of maximum concentration, area under the plasma concentration-time curve from time 0 to the last measurable concentration, and area under the plasma concentration-time curve from time 0 to infinity for the budesonide concentration were 84.8% to 102.7%, 84.6% to 94.4%, and 85.4% to 95.2%, respectively, all fall within the bioequivalent range of 80% to 125%. The test and reference budesonide nasal sprays were PK bioequivalents in healthy Chinese subjects with comparable PK parameters. No serious adverse events were reported, and the 2 products have a good and similar safety profile.</AbstractText><CopyrightInformation>&#xa9; 2021, The American College of Clinical Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yangyang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, Hunan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhenyu</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Sichuan Purity Pharmaceutical Co. LTD, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Shuguang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sichuan Purity Pharmaceutical Co. LTD, Chengdu, Sichuan, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Drug Dev</MedlineTA><NlmUniqueID>101572899</NlmUniqueID><ISSNLinking>2160-763X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016568">Drugs, Generic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059085">Nasal Sprays</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical><Chemical><RegistryNumber>51333-22-3</RegistryNumber><NameOfSubstance UI="D019819">Budesonide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019819" MajorTopicYN="Y">Budesonide</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016568" MajorTopicYN="N">Drugs, Generic</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059085" MajorTopicYN="Y">Nasal Sprays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="N">Therapeutic Equivalency</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bioequivalence</Keyword><Keyword MajorTopicYN="N">budesonide</Keyword><Keyword MajorTopicYN="N">nasal spray</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword><Keyword MajorTopicYN="N">safety</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>16</Day><Hour>9</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34783456</ArticleId><ArticleId IdType="doi">10.1002/cpdd.1036</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Bousquet J, Khaltaev N, Cruz AA, et&#xa0;al. Allergic Rhinitis and Its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(suppl 86):8-160.</Citation></Reference><Reference><Citation>Wang XY, Ma TT, Wang XY, et&#xa0;al. Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of northern China. Allergy. 2018;73(6):1232-1243.</Citation></Reference><Reference><Citation>Bro&#x17c;ek JL, Bousquet J, Agache I, et&#xa0;al. Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017. 140(4): 950-958.</Citation></Reference><Reference><Citation>Chong LY, Head K, Hopkins C, et&#xa0;al. Different types of intranasal steroids for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011993.</Citation></Reference><Reference><Citation>Watts AM, Cripps AW, West NP, et&#xa0;al. Modulation of allergic inflammation in the nasal mucosa of allergic rhinitis sufferers with topical pharmaceutical agents. Front Pharmacol. 2019;10:294.</Citation></Reference><Reference><Citation>Stanaland BE. Once-daily budesonide aqueous nasal spray for allergic rhinitis: a review. Clin Ther. 2004;26(4):473-492.</Citation></Reference><Reference><Citation>Chen H, Lou H, Wang Y, et&#xa0;al. Comparison of the efficacy and mechanisms of intranasal budesonide, montelukast, and their combination in treatment of patients with seasonal allergic rhinitis. Int Forum Allergy Rhinol. 2018;8(11):1242-1252.</Citation></Reference><Reference><Citation>Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol. 2001;108(1 suppl):S26-S31.</Citation></Reference><Reference><Citation>Chen N, Cui D, Wang Q, et&#xa0;al. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes. Xenobiotica. 2018;48(6):637-646.</Citation></Reference><Reference><Citation>Song IH, Finkelman RD, Lan L. A pharmacokinetic bridging study to compare systemic exposure to budesonide between budesonide oral suspension and ENTOCORT EC in healthy individuals. Drugs R D. 2020;20(4):359-367.</Citation></Reference><Reference><Citation>Li BV, Jin F, Lee SL, et&#xa0;al. Bioequivalence for locally acting nasal spray and nasal aerosol products: standard development and generic approval. AAPS J. 2013;15(3):875-883.</Citation></Reference><Reference><Citation>Algorta J, Pena MA, Francisco S, et&#xa0;al. Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations. Trials. 2008;9:34.</Citation></Reference><Reference><Citation>Algorta J, Andrade L, Medina M, et&#xa0;al. Pharmacokinetic bioequivalence of two inhaled tiotropium bromide formulations in healthy volunteers. Clin Drug Investig. 2016;36(9):753-762.</Citation></Reference><Reference><Citation>Du D, Targett D, Stolberg E, et&#xa0;al. A clinical pharmacokinetic study comparing two azelastine hydrochloride nasal formulations in a single-dose design. Eur J Drug Metab Pharmacokinet. 2014;39(1):69-75.</Citation></Reference><Reference><Citation>Eguiluz-Gracia I, Mathioudakis AG, Bartel S, et&#xa0;al. The need for clean air: the way air pollution and climate change affect allergic rhinitis and asthma. Allergy. 2020;75(9):2170-2184.</Citation></Reference><Reference><Citation>Borges NC, Astigarraga RB, Sverdloff CE, et&#xa0;al. Budesonide quantification by HPLC coupled to atmospheric pressure photoionization (APPI) tandem mass spectrometry. Application to a comparative systemic bioavailability of two budesonide formulations in healthy volunteers. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(3-4):236-242.</Citation></Reference><Reference><Citation>Thorsson L, Borg&#xe2; O, Edsb&#xe4;cker S. Systemic availability of budesonide after nasal administration of three different formulations: pressurized aerosol, aqueous pump spray, and powder. Br J Clin Pharmacol. 1999;47(6):619-624.</Citation></Reference><Reference><Citation>Li X, Tong H, Xu B, et&#xa0;al. A sensitive and high-throughput LC-ESI-MS/MS method to detect budesonide in human plasma: application to an evaluation of pharmacokinetics of budesonide intranasal formulations with and without charcoal-block in healthy volunteers. Drug Dev Ind Pharm. 2021;47(2):329-336.</Citation></Reference><Reference><Citation>Au JL, Lu Z, Abbiati RA, et&#xa0;al. Systemic bioequivalence is unlikely to equal target site bioequivalence for nanotechnology oncologic products. AAPS J. 2019;21(2):24.</Citation></Reference><Reference><Citation>Liu Q, Absar M, Saluja B, et&#xa0;al. Scientific considerations for the review and approval of first generic mometasone furoate nasal suspension spray in the United States from the bioequivalence perspective. AAPS J. 2019;21(2):14.</Citation></Reference><Reference><Citation>Steckel H, Wehle S. A novel formulation technique for metered dose inhaler (MDI) suspensions. Int J Pharm. 2004;284(1-2):75-82.</Citation></Reference><Reference><Citation>Thomas BJ, Absar M, Delvadia R, et&#xa0;al. Analytical method development for characterizing ingredient-specific particle size distributions of nasal spray suspension products. J Pharm Sci. 2021;110(7):2778-2788.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33523774</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-5762</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Drug development and industrial pharmacy</Title><ISOAbbreviation>Drug Dev Ind Pharm</ISOAbbreviation></Journal><ArticleTitle>A sensitive and high-throughput LC-ESI-MS/MS method to detect budesonide in human plasma: application to an evaluation of pharmacokinetics of budesonide intranasal formulations with and without charcoal-block in healthy volunteers.</ArticleTitle><Pagination><StartPage>329</StartPage><EndPage>336</EndPage><MedlinePgn>329-336</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/03639045.2021.1879842</ELocationID><Abstract><AbstractText>Budesonide is one of the intranasal corticosteroids, referred as first-line therapy for allergic rhinitis. Its determination is a challenging task due to its extremely low plasma levels, which limits the progress in the investigation of pharmacokinetics and quality control of preparations. In this study, a sensitive and high-throughput method to determine budesonide in human plasma using budesonide-d8 as the internal standard was developed and validated. A small volume of plasma sample (0.2&#x2009;mL) was diluted with 0.2&#x2009;mL water, followed by a solid-phase extraction using Cleanert PEP-2 products. Extracted samples were analyzed by liquid chromatography coupled to electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). Chromatographic separation of analytes was performed on an InertSustain AQ-C18&#x2009;HP column (3&#x2009;&#xb5;m, 2.1&#x2009;&#xd7;&#x2009;50&#x2009;mm) under the reversed-phase condition with gradient elution. With the assay, linear calibration curves were obtained over the concentration range of 10-1200&#x2009;pg/mL for budesonide, with considerable extraction recoveries (84.7-89.4%), and negligible matrix effects (&lt;4.1). Moreover, the newly developed method was successfully applied to the evaluation of pharmacokinetics of two budesonide intranasal formulations with and without charcoal block in healthy volunteers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Bing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Junchen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Chengdu Brilliant Pharmaceutical Co., Ltd, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mengqin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Suzhou Guochen Biotechnology Co., Ltd, Suzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Siwei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, The Third Hospital of Changsha, Changsha, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Drug Dev Ind Pharm</MedlineTA><NlmUniqueID>7802620</NlmUniqueID><ISSNLinking>0363-9045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>16291-96-6</RegistryNumber><NameOfSubstance UI="D002606">Charcoal</NameOfSubstance></Chemical><Chemical><RegistryNumber>51333-22-3</RegistryNumber><NameOfSubstance UI="D019819">Budesonide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019819" MajorTopicYN="N">Budesonide</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002606" MajorTopicYN="Y">Charcoal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002853" MajorTopicYN="N">Chromatography, Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010949" MajorTopicYN="N">Plasma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021241" MajorTopicYN="N">Spectrometry, Mass, Electrospray Ionization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="Y">Tandem Mass Spectrometry</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Budesonide</Keyword><Keyword MajorTopicYN="N">LC-ESI-MS/MS</Keyword><Keyword MajorTopicYN="N">activated charcoal</Keyword><Keyword MajorTopicYN="N">local absorption</Keyword><Keyword MajorTopicYN="N">nasal spray</Keyword><Keyword MajorTopicYN="N">pharmacokinetics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>1</Day><Hour>17</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33523774</ArticleId><ArticleId IdType="doi">10.1080/03639045.2021.1879842</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>